Our story
It started with a belief: human drugs should be developed with human biology
myriamed's story begins, as the best ones do, with people – the scientists, friends and entrepreneurs who shared a deep trust in one another and a belief that drug development could be done differently. They had watched too many promising medicines fail after years of research and investment. And they asked a simple question: Could we bring human biology closer to the earliest stages of drug discovery?
That question became the seed of something larger and in 2012, myriamed was founded, built on decades of research and entrepreneurial efforts stretching back to 2002. Building a company around a new paradigm, particularly in an industry understandably cautious about disturbing established approaches, was never going to be straightforward. It required patience, persistence and trust, but above all, it required an unshakeable belief that the science was strong enough to make the journey worthwhile.
The science came first. The company followed
For decades, Prof. Zimmermann and his team laid the scientific foundations for recreating human biology in the dish, showing that cells could be organized into functional entities and developing engineered muscle that could contract, model disease and ultimately demonstrate therapeutic potential. What began as scientific exploration and foundational tissue engineering gradually transformed into clinical translation and eventually became a conviction: Human biology could and should play a greater role in developing human drugs.
It is this principle that has become the foundation of myriamed. “Human models for human drugs.” myriamed has grown and evolved over the years, but one thing has remained constant: the belief that we can build something meaningful together. What began with a scientific idea and a close-knit group of people has grown into a team bringing that vision to life. And we believe the journey has only just begun.
